Glenmark Gets Nod to Market Montlezir in Russia

October 4, 2019

Glenmark Pharmaceuticals has been granted marketing approval from the Russian Ministry of Healthcare for its film-coated tablets, Montlezir, to treat seasonal and perennial allergic rhinitis.

Glenmark Pharmaceuticals has been granted marketing approval from the Russian Ministry of Healthcare for its film-coated tablets, Montlezir (Levocetirizine Dihydrochloride 5 mg + Montelukast Sodium 10 mg), to treat seasonal and perennial allergic rhinitis in patients aged 15 years and older.

“Glenmark has built strong capabilities in the area of respiratory and is among the leading players in this therapy area across several markets globally. Russia is one of the key markets for us and we are consistently looking to expand our product portfolio,” said Csaba Kantor, senior vice-president and head-Asia, Russia and CIS region, Glenmark Pharmaceuticals, in a Sep. 30, 2019 press release. “We believe that approval for Montlezir will help enhance our presence in this segment.” 

“Allergic rhinitis affects a significant number of people in Russia, and we already have a number of products in our portfolio for the treatment of this condition,” added Oxana Pozdnyakova, vice-president and business head-Russia, Glenmark Pharmaceuticals. “The approval to market Montlezir will further strengthen our company’s position in this segment and we are delighted to be able to bring new products to the market for patients suffering from this condition.”

The tablets are expected to be available in Russia in the third quarter of the 2019–2020 financial year. 

Source: